RxDoctor Payments DataLook up a doctor →

Peiqing Qian, MD

Internal Medicine · Seattle, WANPI 1902026164

Payments from drug & device makers

$1,531,846in general payments, 2019–2025

Across 387 payments — averaging $3958.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$876K
  • TG Therapeutics, Inc.$363K
  • Biogen$150K
  • Genentech, Inc.$72K
  • Bristol Myers Squibb$18K
  • Sanofi$16K
  • plus $37K from 9 others
$21,382in research payments, 2019–2025

Across 19 payments — averaging $1125.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • TG Therapeutics, Inc.$21K
  • Biogen$87

What the payments were for

  • Consulting fees$44,34938%
  • Speaking & faculty fees$49,34642%
  • Travel & lodging$10,4039%
  • Food & beverage$12,17210%
  • Education$4860%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,531,846 in reported general payments places this provider in the 95th percentile of 2,038 internal medicine providers in Washington.

See all internal medicine providers in Washington

Medicare billing

Part B allowed, 2024
$28,709
Medicare patients
81
Services billed
151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate36$206,582
Rebif RebidoseInterferon Beta-1a/Albumin14$147,835
VumerityDiroximel Fumarate15$141,343
Avonex Pen (4 Pack)Interferon Beta-1a11$88,400
Glatiramer Acetate35$49,191
Dimethyl Fumarate24$14,316
Dalfampridine ErDalfampridine56$6,598
Baclofen56$2,264
Gabapentin106$2,150
Mycophenolate Mofetil11$1,826
Tizanidine Hcl46$1,761
Duloxetine Hcl14$1,716
Modafinil16$1,029
Methylphenidate Hcl19$568
Carbamazepine12$325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$7,649$206,58236 claims
BiogenVumerity$150,485$141,34315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,038 internal medicine providers in Washington.

Other internal medicine in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →